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Recommendationliterature review emphasized domestic data, after which the draft statements and statement ev-
idence levels were defined. Thirty-five experts of GERD in Taiwan formed the expert group to
conduct the consensus conference by a modified Delphi process to vote anonymously to reach a
consensus, defined by an agreement of 80% for each statement, and to set the recommendation
grade.
Results: The consensus included 22 statements, including seven on diagnostic approach, seven on
therapeutic suggestion, and eight on unresolved, controversial, or long-term proton pump
inhibitor-related issues to GERD. The consensus highlighted that the endoscopy approach to GERD
can define the disease spectrum and exclude malignant potential. The questionnaire survey can
not only define GERD, but also monitor treatment response and quality of life. The consensus ad-
dressed suggestions for the unresolved issues related to extraesophageal presentation and adverse
concerns of GERD after long-term use of proton pump inhibitors. In the endemic area of upper
gastrointestinal cancers, Helicobacter pylori eradication is suggested to reduce progression of
gastric precancerous lesions, and endoscopic surveillanceof Barrett’s esophaguswith dysplasia de-
serves prospective research.
Conclusion: The consensus comprises recommendations for themanagement of GERD in a high up-
per gastrointestinal cancer area with a national coverage of endoscopic approach.
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Taiwan and Taiwan Association for the Study of the Liver. Published by Elsevier Taiwan LLC.
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Diagnosis and treatment of gastroesophageal reflux disease
(GERD) are becoming more important [1e4]. GERD has not
only chronic recurrent bothersome clinical symptoms, but
also long-term impacts on the quality of life and perfor-
mance of diseased individuals. In the Western world, due to
a low prevalence of esophageal cancer and upper gastro-
intestinal malignancy, empiric antisecretory medication,
such as proton pump inhibitors (PPIs), has been widely
applied for patients with typical presentations such as acid
regurgitation or heart burn sensation at the epigastric or
midchest regions to indicate reflux-related disorders [4e8].
Nevertheless, the current role of esophageal endoscopy
remains helpful to confirm the diagnosis of erosive esoph-
agitis and then to validate the degree of esophageal mu-
cosa defects according to the Los Angeles grading
classification [9e14]. The different disease spectrums, such
as erosive or nonerosive GERD, will have different treat-
ment modalities. Accordingly, even PPI can be empirically
started in the Western world, the role of endoscopic-based
approach for GERD shall remain with more accurate diag-
nostic determination to the disease spectrum and to
exclude the malignant potentials of upper gastrointestinal
tract in the Eastern world with high cancer endemics.
In Taiwan, endoscopy can be covered by the Taiwan
National Health Insurance program, and based on the
endoscopic findings to define the disease spectrum of
GERD, PPIs can be allowed for durations ranging from at
least 4 months up to 12 months. Accordingly, a nationwide
model is required to offer an objective evidence of erosive
GERD control. The advantage of the current consensus is
that it offers Taiwanese experts’ experiences with
endoscopic-based approach supported by the National
Health Insurance in a near 95% nationwide coverage. The
current consensus has provided a strong evidence of its
validity for GERD management in a nationwide cohort
setting, including the diagnostic approach and therapeuticassessment. The consensus also addressed important con-
cerns to highlight the unresolved, controversial, and long-
term issues of GERD for future improvement in such
endemic area with upper gastrointestinal cancers.
Methods
Steering committee set the consensus scope and
structure
To establish the expert consensus of GERD in Taiwan, the
steering committee was initiated by J.T. Lin, chaired by
B.S. Sheu along with eight other opinion leaders from the
Gastroenterological Society of Taiwan (C.T. Chiu, Y.C. Lee,
G.Y. Chang, D.C. Wu, C.M. Liou, M.S. Wu, W.L. Chang, and
C.Y. Wu). The steering committee defined the scope ses-
sions of the consensus, conducted a literature search and
review, formulated draft statements, and defined the
statement evidence level.
Steering committee members to conduct literature
search and review
The literature searches included Medline, Embase, the
Cochrane Central Register of Controlled Trial, and ISI Web
of Knowledge, with manual searches of bibliographies of
key articles and proceedings of abstracts of major gastro-
enterology conferences held over the past 7 years. The key
words used in the search included gastroesophageal reflux,
PPI, Barrett’s esophagus, extraesophageal symptoms, nar-
row band image, upper gastrointestinal endoscopy, etc.
The members of the steering committee summarized the
findings in the three scope sessions of this consensus: (1)
diagnostic approach; (2) therapeutic assessment; and (3)
unresolved, controversial, or long-term PPI-related issues
associated with GERD. Based on the review of the litera-
ture, the draft statements of the consensus were
Statement I-2: The validated questionnaire is useful
in the diagnosis of GERD, monitoring of treatment
response, and evaluation of quality of life.
(agreement: 100%, level of evidence: 3b, recom-
mendation: A)
Statement I-3: In Taiwan where upper GI malignancies
remain prevalent, upper GI endoscopy is useful to
evaluate the diagnosis, set the disease spectrum of
GERD, and exclude the possibility of cancer.
(agreement: 97%, level of evidence: 3a, recom-
mendation: A)
Taiwan expert consensus on GERD 87established by the session leader(s) of each scope session.
For each statement, the level of evidence was defined ac-
cording to modified grading of the Oxford Centre for
Evidence-Based Medicine Levels of Evidence (March 2009),
as applied in our previous consensus [15]. The draft state-
ments were refined at the steering committee meeting held
in Kaohsiung, Taiwan during June 2014.
Expert group meeting to achieve agreement of
statement and recommendation grading
A total of 35 experts (the names are listed in the supple-
mentary data), including 10 members in the steering com-
mittee and 25 members who accepted the invitation of the
steering committee, comprised the expert group of the
Taiwan GERD consensus. The draft statements from the
four session groups were sent to all the experts, together
with pertinent literature, prior to the consensus meeting in
Kaohsiung in August 2014.
During the 2-day consensus meeting, for each draft
statement from the four scope sessions, the supporting ev-
idence from the keynote literature summary by the steering
committee was presented serially in the following order:
cover diagnostic, therapeutic, unresolved, controversial,
long-term PPI-related issues for GERD. Based on a modified
Delphi process through two separate iterations, all partici-
pants voted anonymously for the first round of statements
and modified the statements through discussion. The modi-
fied statements were followed by a second round of voting
with electronic keypads until a consensus was reached at the
agreement percentage of  80%. If the agreement was <
80%, the statement was rejected. The expert members also
discussed the level of evidence suggested by the steering
committee and then graded the recommendation level by
voting for each statement. The grade of recommendation
ranged from A to D, as was used in our previous consensus in
Taiwan [15]. The level of recommendation was defined as
the grade with the highest number of votes of the expert
group members. The conferences were underwritten by
unrestricted grants from the Gastroenterological Society of
Taiwan. Mandatory written disclosures of financial conflicts
of interest within the period of 3 years prior to the meetings
were obtained from all experts prior to voting.
Consensus statements
Section I: diagnostic approachStatement I-1: In Taiwan, the prevalence of GERD is
increasing while that of Helicobacter pylori infection
is declining.
(agreement: 100%, level of evidence: 2a, recom-
mendation: A)In Taiwan, both the endoscopic indication and the diagnosis
of GERD have substantially increased, and the increasing
trend of GERD is likely related to a higher proportion of low-
grade erosive esophagitis detected by endoscopy [16]. The
possible reason can be related to the increase in population
with obesity and metabolic syndrome [17,18]. Anotherpossible reason is related to Helicobacter pylori eradication
as a common practice for the treatment of the intragastric
pathology. A previous meta-analysis showed a significant
association between absence of H. pylori infection and
GERD symptoms, and a positive association between anti-H.
pylori therapy and occurrence of both de novo and
rebound/exacerbated GERD [19]. In a community-based
screening program in Taiwan, eradication of H. pylori
infection has led to increased esophagitis [20]. Although
the causal relationship between GERD and H. pylori infec-
tion may be confounded by other etiologies, an inverse
association is generally observed.Several validated questionnaires have been developed
for the assessment of GERD. Clinical applications of the
GERD questionnaires may include the diagnosis of GERD,
assessment of treatment response, and evaluation of GERD
symptoms and their effects on the quality of life. For
example, the GERD Questionnaire has been proved to be a
useful tool to diagnose GERD with an area under the
receiver operating characteristic curve of 0.7 [21]. A higher
GERD Questionnaire score is significantly correlated with a
higher risk of erosive esophagitis [22]. The Reflux Disease
Questionnaire, which includes both the presence of symp-
toms and the severity/frequency of GERD, has been found
to be useful in monitoring its therapeutic response to PPIs
[23,24]. The Short-Form 36 questionnaire has been used in
the evaluation of health status and quality of life in GERD
patients [25].In Taiwan, concomitant GERD symptoms are commonly
observed in patients with upper aerodigestive tract neo-
plasms, and approximately two-thirds of the patients with
fresh hypopharyngeal cancer have erosive esophagitis,
active H. pylori infection, or gastric/duodenal ulcers [26].
In patients with gastric cancer, similarly, concomitant
GERD/dyspepsia symptoms are very common [27]. There-
fore, in this population with prevalent upper GI malig-
nancies, upper endoscopy is well accepted by
gastroenterologists as the first-line diagnostic tool for the
evaluation of GERD symptoms, categorization of disease
spectrum of GERD (such as erosive GERD and non-erosive
reflux disease (NERD)), and most importantly, exclusion of
the possibility of upper GI tract cancer.
Statement I-4: PPI-first approach may be considered
for the treatment-naı¨ve patients with low risk of
upper GI cancer or patients with relapse GERD symp-
toms shortly after treatment.
(agreement: 100%, level of evidence: 3a, recom-
mendation: A)
Statement I-7: In selected patients for whom invasive
diagnostic testing of GERD is not feasible, esophageal
radiographic or scintigraphic study could be an
option.
(agreement: 82%, level of evidence: 4, recommen-
dation: B)
88 B.-S. Sheu et al.PPIs are the most effective drugs to suppress gastric acid
secretion and relieve reflux symptoms. Therefore, an
empirical short course (usually 7e14 days) of PPIs, the so-
called PPI test, is useful in the diagnosis of GERD [28,29]. In
patients with GERD symptoms, a previous meta-analysis has
shown pooled sensitivity and specificity of 71% and 41%,
respectively [30]. The data indicated that the PPI test was
sensitive, but less specific. In patients with noncardiac
chest pain, the PPI test showed pooled sensitivity and
specificity of 80% and 74%, respectively, to confirm GERD
[31]. A meta-analysis indicated that the optimal duration
may be 1 week and the optimal cutoff value should be a
decrease of heartburn score by > 75% [32].Statement I-5: Image-enhanced endoscopy with or
without magnification may help diagnosis of patients
with NERD and predict who will respond to PPI.
(agreement: 88%, level of evidence: 3a, recom-
mendation: B)
Statement II-1: In GERD patients with persistent
symptoms despite PPI therapy, double-dosing or
switching to a different PPI after ensuring the
compliance may provide symptoms relief.
(agreement: 94%, level of evidence: 1b, recom-
mendation: B)Image-enhanced endoscopy provides a significant
improvement over standard white-light imaging for the
diagnosis of nonerosive GERD, with better visualization of
subtle erosive changes in the esophagus. The sensitivity and
specificity of narrow-band images in differentiation of
nonerosive reflux diseases and controls were 65% and 83%,
respectively, based on the presence of dilated intra-
papillary capillary loops under endoscopic magnification
[33]. The inter- and intraobserver agreement in the grading
of endoscopic esophagitis could be improved when image-
enhanced endoscopy was used [34e36]. Certain specific
narrow band image findings can even correlate with a
positive therapeutic response [37].Statement I-6: In patients with atypical or refractory
GERD symptoms, esophageal function studies, such as
manometry, pH meter, or impedance-pH monitoring,
may be useful in the investigation of etiology.
(agreement: 100%, level of evidence: 3a, recom-
mendation: A)
Statement II-2: PPI treatment with on-demand or
continuous therapy can be administered for GERD
patients with symptoms relapse.
(agreement: 97%, level of evidence: 1a, recom-
mendation: A)In patients with atypical or refractory GERD symptoms,
it is important to identify those with true GERD and other
etiology mimicking GERDs such as atypical presentation of
achalasia and some of esophageal motility disorders
[38,39]. Additional diagnosis with esophageal manometry
and 24-hour pH monitoring is required to detect other dis-
ease entities that may manifest like GERD [40,41]. The
addition of impedance to conventional 24-hour pHmonitoring improves diagnosis by showing weak acidic and
nonacidic refluxes [42]. In patients with refractory GERD
symptoms, the true diagnosis of GERD can be confirmed by
abnormal acid exposure on 24-hour PH monitoring. By
contrast, negative results of PH monitoring suggest that
symptoms are unlikely due to acid reflux [43].Traditional diagnoses of GERD, including endoscopy,
manometry, and pH studies, may be cumbersome in some
cases, such as in patients who have undergone total or
proximal gastrectomy, those with nasogastric tube or gas-
trostomy, and children. Esophageal radiographic or scinti-
graphic studies can be an alternative choice to define the
presence of GERD [44,45]. More specifically, radionuclide
scintigraphy may provide important diagnostic clues under
special conditions, and the reported sensitivities of
esophageal scintigraphy in the diagnosis of GERD could be
up to 76% [46,47].Section II: therapeutic assessmentPersistent heartburn and other upper gastrointestinal
symptoms despite PPI therapy have become clinical prob-
lems that are increasing in gastroenterology practices.
Approximately 25% of PPI recipients will require higher
doses than initially prescribed because of insufficient con-
trol of GERD symptoms or lack of healing of the esophageal
mucosa [48]. A randomized control trial suggested that
double dosing of lansoprazole or switching to esomeprazole
can deal with patients suffering from persistent symptoms
despite lansoprazole therapy [49]. More studies confirming
similar effectiveness of double dosing or switching to a
different PPI can really be helpful.
Statement II-6: Barrett’s esophagus remains uncom-
mon in Taiwan compared with Western countries.
(agreement: 100%, level of evidence: 3a, recom-
mendation: A)
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symptomatic remission and improvement of quality of life
between on-demand and continuous therapy with PPIs for
GERD [50e52]. However, continuous therapy has a higher
healing rate of erosive esophagitis [53,54]. However, most
of the studies focus on mild GERD cases. Further studies
should be undertaken to investigate severe GERD.Statement II-3: The response to PPI therapy for
symptoms relief in patients with non-erosive reflux
disease is generally lower than that in those with
erosive esophagitis.
(agreement: 97%, level of evidence: 1a, recom-
mendation: A)A multicenter study showed that the heartburn resolu-
tion rates at 4 weeks were higher for patients with erosive
esophagitis than for those with nonerosive esophagitis [55].
A systemic review reveals that PPI can provide higher
therapeutic gain for heartburn resolution in patients with
nonerosive reflux disease than in those with erosive
esophagitis.Statement II-4: PPI therapy for NERD patients may be
augmented with prokinetics and alginates.
(agreement: 82%, level of evidence: 1b recommen-
dation: B)
Statement II-7: Prague C and M criteria is recom-
mended in the endoscopic description of Barrett’s
esophagus.
(agreement: 94%, level of evidence: 3a, recom-
mendation: B)Administration of mosapride citrate in addition to
omeprazole improved GERD symptoms and gastric emptying
in PPI-resistant nonerosive GERD patients with delayed
gastric emptying [56]. Another study illustrated that
omeprazole combined with sodium alginate provided higher
resolution of heartburn than omeprazole alone in patients
with nonerosive GERD [57]. Due to the limited case
numbers in the previous two studies, more evidence is
anticipated in future studies.Statement II-5: GERD patients with higher BMI will
have poorer symptoms relief by PPI treatment.
(agreement: 97%, level of evidence: 2a, recom-
mendation: A)There was a strong positive association between body
mass index (BMI) and symptoms of GERD in a large cohort of
women [58]. For Los Angeles Grade A or B reflux esopha-
gitis, a higher BMI decreases the rate of sustained symp-
tomatic response after 8 weeks of esomeprazole therapy,
and increases the need for medication and the failure rate
of on-demand therapy [13]. In addition, a BMI of > 25 kg/m2
is an independent risk factor to determine the healing of
Los Angeles Grade C or D reflux esophagitis by esomepra-
zole [14]. Reducing BMI to > 1.5 kg/m2, especially for those
with an initial BMI of > 25 kg/m2, could be promising to
improve the healing of RE-CD by esomeprazole [14].The prevalence of Barrett’s esophagus in Taiwan was
0.06e2.0%, and it varies with study design [59e62]. Chen
et al [16] found that the prevalence of Barrett’s esophagus
did not change over time, although the prevalence of GERD
was increasing. Chang et al [61] used a prospective design
with a standardized biopsy protocol and histological
confirmation for Barrett’s esophagus to include both
symptomatic and asymptomatic patients from a large
ethnic Chinese population. The prevalence (0.85%) of Bar-
rett’s esophagus in this study is lower than that in Western
countries. The prevalence of Barrett’s esophagus varies
from 2.4% to 13.6% in Western countries, according to some
studies [63e66], using the same design (prospective
enrollment, endoscopic biopsy from standard four quad-
rants, pathological confirmation, and a large case number).The utility of Prague C and M criteria has been proved by
a large prospective study in Taiwan [61]. A multinational
endoscopic study showed that the intraclass correlation
coefficient value for the scores of the C value was 0.92 and
that for M value was 0.94, indicating an excellent inter-
observer agreement [67]. In other words, Prague C and M
criteria have good validity and reliability for description of
Barrett’s esophagus. However, a long-term follow-up study
should be conducted to verify the relationship between the
clinical outcome of Barrett’s esophagus and the severity of
Prague C and M values.Section III: unresolved, controversial, or long-term
care issues
Extraesophageal syndromes, including chronic cough,
asthma, and chronic laryngitis, are present in a substantial
proportion of patients with gastroesophageal reflux disease
[68]. However, management of these extraesophageal
symptoms remains debatable in clinical practice [68e73].
Whether PPI therapy is beneficial in the management of
these symptoms has attracted much attention. Whether
long-term PPI therapy and surveillance programs may
reduce the risk and mortality of esophageal adenocarci-
noma, respectively, in patients with Barrett’s esophagus
are also important clinical issues [74e77]. Whether long-
term PPI users have a higher risk of potential adverse ef-
fects, such as fracture and enteric infection, is also a
controversial issue [78e84]. Another important issue is
90 B.-S. Sheu et al.whether screening and eradication of H. pylori are indi-
cated in patients receiving long-term PPI therapy for GERD.Statement III-1: Proton pump inhibitor therapy may
reduce cough in patients with typical reflux symptoms
and chronic cough.
(agreement: 94%, level of evidence: 1a, recom-
mendation: B)
Statement III-4: Long-term proton pump inhibitor
therapy may reduce the risk of high grade dysplasia
and esophageal adenocarcinoma in patients with
Barrett’s esophagus.
(agreement: 91%, level of evidence: 2a, recom-
mendation: B)
Statement III-5: Endoscopic surveillance in patients
with Barrett’s esophagus is recommended for high risk
groups, although the cost-effectiveness remains
debatable.
(agreement: 100%, level of evidence: 2b, recom-
mendation: A)Of the nine adult studies that compared PPI with pla-
cebo for various outcomes, four (N Z 116 and N Z 75 for
PPI and placebo groups, respectively) assessed the clinical
failure defined as still coughing at the end of the trial or
reporting period [2]. A meta-analysis showed no significant
difference between PPI therapy and placebo in total reso-
lution of cough (odds ratio 0.46; 95% confidence interval
0.19e1.15) [68]. However, a significant improvement in
cough scores was observed in cross-over trials [68]. Never-
theless, the small sample size and the use of different
outcomes were the major limitations of this meta-analysis.
Further well-designed large clinical trials on this issue are
warranted.Statement III-2: In adult asthma patients with typical
reflux symptoms, proton pump inhibitor therapy may
improve pulmonary function.
(agreement: 82%, level of evidence: 1a, recom-
mendation: B)A meta-analysis including 2524 patients showed that PPI
therapy may improve the morning peak expiratory flow, as
compared to placebo, in adult asthma patients with reflux
symptoms [69]. However, PPI therapy was not effective in
asthma patients who did not report reflux symptoms and in
pediatric asthma patients [69e72]. Besides, the clinical
significance of the magnitude of this improvement remains
debatable [69,70]. Further trials are warranted to identify
the subgroup of patients that might benefit more from PPI
therapy.Statement III-3: There is insufficient evidence to
support proton pump inhibitor therapy can improve
laryngeal symptoms in suspected GERD-related
chronic laryngitis.
(agreement: 97%, level of evidence: 1a, recom-
mendation: B)
Statement III-6: Although observational studies
showed the association of long-term use of proton
pump inhibitor with hip and vertebral fracture, the
causal relationship remains uncertain.
(agreement: 100%, level of evidence: 2a, recom-
mendation: B)A meta-analysis failed to show a significant symptom
reduction by PPI therapy in patients with chronic laryngitis
[73]. However, the study scale is limited in usual and defi-
nition of chronic laryngitis with diversity among different
studies in meta-analysis [73,74].A meta-analysis of five cohort studies (N Z 1666) and
two caseecontrol studies (N Z 1147) showed that long-
term PPI therapy was associated with a 71% reduction in
the risk of high-grade dysplasia and esophageal adenocar-
cinoma in patients with Barrett’s esophagus [75]. There was
also a trend that the benefit was more prominent in pa-
tients receiving PPI therapy for longer than 2e3 years [75],
but randomized trials on this issue are lacking.Nationwide population-based cohort studies showed
that the annual incidence of esophageal adenocarcinoma
ranged from 0.15% to 0.19% in males and from 0.05% to
0.08% in females in unselected patients with Barrett’s
esophagus [76]. A retrospective cohort study showed that
the proportion of high-grade dysplasia and esophageal
adenocarcinoma detected was higher among patients with
low-grade dysplasia who underwent endoscopic surveil-
lance every 3 months or less [77]. Considering the low
incidence of esophageal cancer and high cost of endoscopy,
endoscopic surveillance is recommended only for high-risk
patients. Risk factors for progression to esophageal can-
cer include male gender, longer duration of Barrett’s
esophagus, higher BMI, higher waist-to-hip ratio, longer
length of the Barrett’s esophagus segment, presence of
hiatal hernia, visible nodularity detected by endoscopy,
higher degree of dysplasia, etc. [76,77]. Future prospective
cohort studies and intervention trials are warranted to
suggest the optimal intervals of endoscopic surveillance for
Barrett’s esophagus.A meta-analysis of four cohort studies and six case-
econtrol studies, including 223,210 fracture cases, showed
increased risks of hip and vertebral, but not of wrist/fore-
arm, fractures in PPI users [77]. However, PPI use was not
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[78,79,84]. Therefore, the causal relationship of the asso-
ciation detected by observational studies remains uncer-
tain because the possibility of confounding by indication
could not be excluded. Therefore, well-designed random-
ized trials are warranted to clarify the causal relationships
of the association.Statement III-7: Although observational studies
showed the association of long-term use of proton
pump inhibitor with Clostridium difficile associated
diarrhea, the causal relationship remains uncertain.
(agreement: 94%, level of evidence: 2a, recom-
mendation: B)A meta-analysis of six cohort studies and 17 case-
econtrol studies, including close to 300,000 patients,
showed increased risks of Clostridium difficile-associated
diarrhea among patients on long-term PPI therapy [79,80].
Similarly, randomized trials are warranted to confirm or
refute the causal relationships of the association.Statement III-8: Eradication of Helicobacter pylori
improves gastritis and prevents progression of gastric
atrophy and intestinal metaplasia and is recom-
mended in patients on long-term proton pump inhib-
itor therapy.
(agreement: 94%, level of evidence: 1a, recom-
mendation: A)Earlier observational studies showed an increased risk of
atrophic gastritis in patients with reflux esophagitis and
Helicobacter pylori infection that were treated with PPI
therapy [82]. The subsequent four randomized control trials
that included 546 patients further showed that gastric
inflammation could be reduced by H. pylori eradication
[3,82e84]. Longer follow-up periods are warranted to
assess whether the risk of atrophic gastritis or intestinal
metaplasia in long-term PPI users can really be controlled
by H. pylori eradication.
Dissemination strategies and legal issues
These statements are based on the best available evidence
to pursue better quality of care and will be updated every 5
years. They are not suitable for deciding the standard of
care in specific cases. This consensus statement will be
disseminated through the following: (1) presentations given
at the annual society meeting of Taiwan Digestive Week in
2014; (2) release of the copies of these statements in
electronic and paper format to national societies/associa-
tions of gastroenterologists for their iterations; and (3)
release on the website of our society link.
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